Nosocomial Outbreak of Infections by Proteus mirabilis That Produces Extended-Spectrum CTX-M-2 Type β-Lactamase
Authors:
Open Access
- 1 December 2003
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 41 (12) , 5530-5536
Abstract
Nineteen multidrug-resistant Proteus mirabilis strains were isolated from 19 patients suffering from infections probably caused by P. mirabilis . These strains were recovered from urine or other urogenital specimens of 16 inpatients and three outpatients with a hospitalization history in a urology ward of Funabashi Medical Center, from July 2001 to August 2002. These strains demonstrated resistance to cefotaxime, ceftriaxone, cefpodoxime, and aztreonam, while they were highly susceptible to ceftazidime (MIC, ≤0.5 μg/ml). The resistance level of these strains to cefotaxime was decreased by the presence of clavulanic acid. Therefore, the strains were speculated to produce extended-spectrum class A β-lactamases. These strains were later found to carry bla CTX-M-2 genes by both PCR and sequencing analyses. The profiles of Sma I-digested genomic DNA of 19 isolates were distinguished into five different clusters by biased sinusoidal field gel electrophoresis. Four of them, consisting of 18 isolates, were suggested to be a clonal expansion. These findings suggested that a nosocomial outbreak of infections by CTX-M-2-producing P. mirabilis had occurred in our medical center. Most patients suffered from urogenital malignancies with long-term catheterization. Cefazolin, cefoperazone-sulbactam, and/or levofloxacin were mostly administered to the patients, but these agents seemed ineffective for eradication of CTX-M-2 producers. Early recognition and rapid identification of colonizing antimicrobial-resistant bacteria, including CTX-M-2-producing P. mirabilis , would be the most effective measures to cope with further spread of this kind of hazardous microorganism in clinical environments.Keywords
This publication has 41 references indexed in Scilit:
- Diversity of CTX-M β-lactamases and their promoter regions fromEnterobacteriaceaeisolated in three Parisian hospitalsFEMS Microbiology Letters, 2002
- Emerging Extended-Spectrum β-Lactamases in Proteus mirabilisJournal of Clinical Microbiology, 2002
- Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance ThreatClinical Microbiology Reviews, 2001
- Plasmid-mediated extended-spectrum β-lactamase (CTX-M-3 like) from India and gene association with insertion sequence ISEcp1FEMS Microbiology Letters, 2001
- Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of β-lactam/β-lactamase inhibitor combinationsInternational Journal of Antimicrobial Agents, 2001
- Prevalence of β-Lactamases among 1,072 Clinical Strains of Proteus mirabilis : a 2-Year Survey in a French HospitalAntimicrobial Agents and Chemotherapy, 2000
- CTX-M-type β-lactamases: an emerging group of extended-spectrum enzymesInternational Journal of Antimicrobial Agents, 2000
- Two novel plasmid-mediated cefotaxime-hydrolyzing β-lactamases (CTX-M-5 and CTX-M-6) fromSalmonella typhimuriumFEMS Microbiology Letters, 1998
- Extended-spectrum β-lactamase in Proteus mirabilisJournal of Antimicrobial Chemotherapy, 1994
- Close amino acid sequence relationship between the new plasmid-mediated extended-spectrum β-lactamase MEN-1 and chromosomally encoded enzymes of Klebsiella oxytocaBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1992